These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18798614)

  • 21. Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples.
    Végvári A; Rezeli M; Häkkinen J; Sihlbom C; Carlsohn E; Malm J; Lilja H; Laurell T; Marko-Varga G
    J Proteomics; 2011 Dec; 75(1):202-10. PubMed ID: 21723425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
    Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
    Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM; Finne P; Leinonen J; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
    Fukushima K; Satoh T; Baba S; Yamashita K
    Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients.
    Wimmers F; de Haas N; Scholzen A; Schreibelt G; Simonetti E; Eleveld MJ; Brouwers HM; Beldhuis-Valkis M; Joosten I; de Jonge MI; Gerritsen WR; de Vries IJ; Diavatopoulos DA; Jacobs JF
    Sci Rep; 2017 Mar; 7():43486. PubMed ID: 28344338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A sulfanyl-PEG derivative of relaxin-like peptide utilizable for the conjugation with KLH and the antibody production.
    Katayama H; Mita M
    Bioorg Med Chem; 2016 Aug; 24(16):3596-602. PubMed ID: 27288185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors.
    Hilz H; Noldus J; Hammerer P; Buck F; Lück M; Huland H
    Eur Urol; 1999 Oct; 36(4):286-92. PubMed ID: 10473986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemocyanin from the keyhole limpet Megathura crenulata (KLH) carries a novel type of N-glycans with Gal(beta1-6)Man-motifs.
    Kurokawa T; Wuhrer M; Lochnit G; Geyer H; Markl J; Geyer R
    Eur J Biochem; 2002 Nov; 269(22):5459-73. PubMed ID: 12423344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation of isodesmosine-KLH conjugate for ELISA system.
    Baut DA; Tanaka N; Yokoo R; Usuki T
    Chirality; 2020 Apr; 32(4):431-436. PubMed ID: 32027414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-protein conjugates: preparation of triamcinolone-acetonide containing bovine serum albumin/keyhole limpet hemocyanin-conjugates and polyclonal antibodies.
    Gabor F; Pittner F; Spiegl P
    Arch Pharm (Weinheim); 1995 Dec; 328(11-12):775-80. PubMed ID: 8585789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haliotis tuberculata hemocyanin (HtH): analysis of oligomeric stability of HtH1 and HtH2, and comparison with keyhole limpet hemocyanin KLH1 and KLH2.
    Harris JR; Scheffler D; Gebauer W; Lehnert R; Markl J
    Micron; 2000 Dec; 31(6):613-22. PubMed ID: 10838022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural diversity of cancer-related and non-cancer-related prostate-specific antigen.
    Isono T; Tanaka T; Kageyama S; Yoshiki T
    Clin Chem; 2002 Dec; 48(12):2187-94. PubMed ID: 12446475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro affinity maturation of an anti-PSA antibody for prostate cancer diagnostic assay.
    Muller BH; Savatier A; L'Hostis G; Costa N; Bossus M; Michel S; Ott C; Becquart L; Ruffion A; Stura EA; Ducancel F
    J Mol Biol; 2011 Dec; 414(4):545-62. PubMed ID: 22019475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids.
    White KY; Rodemich L; Nyalwidhe JO; Comunale MA; Clements MA; Lance RS; Schellhammer PF; Mehta AS; Semmes OJ; Drake RR
    J Proteome Res; 2009 Feb; 8(2):620-30. PubMed ID: 19128049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
    Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
    Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard.
    Bélanger A; van Halbeek H; Graves HC; Grandbois K; Stamey TA; Huang L; Poppe I; Labrie F
    Prostate; 1995 Oct; 27(4):187-97. PubMed ID: 7479385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells.
    Saedi MS; Zhu Z; Marker K; Liu RS; Carpenter PM; Rittenhouse H; Mikolajczyk SD
    Int J Cancer; 2001 Nov; 94(4):558-63. PubMed ID: 11745444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.
    Elkord E; Williams PE; Kynaston H; Rowbottom AW
    Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
    Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.
    Xie C; Kim HJ; Haw JG; Kalbasi A; Gardner BK; Li G; Rao J; Chia D; Liong M; Punzalan RR; Marks LS; Pantuck AJ; de la Taille A; Wang G; Mukouyama H; Zeng G
    J Transl Med; 2011 Apr; 9():43. PubMed ID: 21504557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.